Unique ID issued by UMIN | UMIN000053883 |
---|---|
Receipt number | R000061501 |
Scientific Title | Exploratory Study on Diagnostic Performance of Multi-Cancer using Machine Learning Models with Urinary Biomarkers |
Date of disclosure of the study information | 2024/03/18 |
Last modified on | 2024/03/18 10:38:34 |
Exploratory Study on Diagnostic Performance of Multi-Cancer using Machine Learning Models with Urinary Biomarkers
Exploratory Study on Diagnostic Performance of Multi-Cancer using Machine Learning Models with Urinary Biomarkers
Exploratory Study on Diagnostic Performance of Multi-Cancer using Machine Learning Models with Urinary Biomarkers
Exploratory Study on Diagnostic Performance of Multi-Cancer using Machine Learning Models with Urinary Biomarkers
Japan |
Lung cancer, breast cancer, colon cancer, stomach cancer, esophagus cancer, ovary cancer, kidney cancer, urothelial cancer, prostate cancer, cervix cancer, brain tumor
Gastroenterology | Hepato-biliary-pancreatic medicine | Pneumology |
Nephrology | Neurology | Surgery in general |
Gastrointestinal surgery | Hepato-biliary-pancreatic surgery | Chest surgery |
Breast surgery | Laboratory medicine | Adult |
Malignancy
NO
1. miRNA Analysis
We analyze the comprehensive miRNA profiles obtained from miRNA extracted from urine specimens of various cancer patients, brain tumor patients, and healthy adults, evaluating their correlation with clinical information obtained from routine examinations. For cancer types targeted by miSignal as of March 2024, our aim is to assess the improvement in diagnostic performance of predictive models, while for cancer types not targeted as of March 2024, we will construct new predictive models and evaluate the performance of these constructed models.
2. DNA Methylation Analysis
We comprehensively analyze the methylation patterns of cfDNA extracted from urine specimens of various cancer patients, brain tumor patients, and healthy adults, evaluating their correlation with clinical information obtained from routine examinations. In this analysis, we aim to construct new predictive models for all cancer types and evaluate the performance of these constructed predictive models.
Others
Exploratory Analysis of Other Urinary Biomarkers
We measured and analyzed other biomarkers (such as nucleic acids, proteins, metabolites, urinary constituents, etc.) extracted from urine specimens of various cancer patients, brain tumor patients, and healthy adults, and evaluated their correlation with clinical information obtained from routine examinations. In this analysis, we aim to explore the possibility of constructing new predictive models for all cancer types and brain tumors as listed in Table 2-1.
Exploratory
Others
Not applicable
The specimens collected in this study are allocated to training and test datasets in approximately a 2:1 ratio. Using either miRNA expression levels or DNA methylation rates as features, machine learning is employed to construct predictive models optimized for the diagnostic performance of each cancer type and brain tumor. The diagnostic performance for each cancer type and brain tumor is evaluated using statistical measures such as AUC values, sensitivity, and specificity. In the analysis based on miRNA expression levels, for cancer types currently targeted by miSignal, a comprehensive evaluation with existing predictive models (e.g., through cross-validation) is conducted. As for other urinary biomarkers, since it is in an exploratory stage, specific evaluation criteria will be established using these specimens.
This study is a non-interventional clinical research, and there are no health risks to the study participants. Therefore, no information regarding safety is collected.
Observational
18 | years-old | <= |
Not applicable |
Male and Female
For Cancer Patients and Brain Tumor Patients
To participate in this study, individuals must meet all of the following criteria (1) to (4):
1. At the time of signing the consent form, the individual must be a Japanese national aged 18 years or older.
2. Using a consent document approved by the ethics review committee of each research institution, written consent must be obtained based on the free will of the individual or their proxy for participation in this study.
3. The individual must have been pathologically diagnosed with one of the following cancers or brain tumors with a clear primary site. The histological type and stage of cancer, as well as the classification and malignancy of brain tumors, are not relevant.
Lung cancer, breast cancer, colorectal cancer, stomach cancer, esophageal cancer, ovarian cancer, kidney cancer, urinary tract epithelial cancer, prostate cancer, cervical cancer
4. At the time of urine specimen collection, the individual must not have a history of treatment for cancer or brain tumors.
For Healthy Adults
To participate in this study, individuals must meet all of the following criteria (1) to (3):
1. At the time of signing the consent form, the individual must be a Japanese national aged 50 years or older.
2. Using a consent document approved by the Institutional Review Board (IRB) of each research institution, written consent must be obtained based on the free will of the individual.
3. Based on medical evaluation including medical history, physical examination, vital signs (blood pressure, pulse rate), and clinical laboratory tests, individuals must be determined by a physician to be in good health.
Individuals who meet any of the following criteria (1) to (5) at the time of specimen collection are not eligible to participate in this study:
(1) Those who are pregnant or may be pregnant.
(2) Women who are menstruating.
(3) Those with a history of malignant tumors or brain tumors.
(4) Those currently participating in intervention trials (including clinical trials) other than this study.
(5) Any other individuals deemed inappropriate by the physician of the research institution.
900
1st name | Yuki |
Middle name | |
Last name | Ichikawa |
Craif. Inc
Chief Technology Officer
113-0034
5F ITP Hongo Office , 2-25-7 Yushima, Bunkyo-ku, Tokyo, 113-0034, Japan
03-6801-8334
clinicaltrial@craif.com
1st name | Motoki |
Middle name | |
Last name | Mikami |
Craif inc.
Clinical Development
113-0034
5F ITP Hongo Office , 2-25-7 Yushima, Bunkyo-ku, Tokyo, 113-0034, Japan
03-6801-8334
clinicaltrial@craif.com
Craif Inc.
self funded
Profit organization
Craif Institutional Review Board
5F ITP Hongo Office , 2-25-7 Yushima, Bunkyo-ku, Tokyo, 113-0034, Japan
03-6801-8334
clinicaltrial@craif.com
NO
2024 | Year | 03 | Month | 18 | Day |
Unpublished
Preinitiation
2024 | Year | 01 | Month | 30 | Day |
2024 | Year | 03 | Month | 07 | Day |
2024 | Year | 04 | Month | 30 | Day |
2025 | Year | 03 | Month | 31 | Day |
None
2024 | Year | 03 | Month | 18 | Day |
2024 | Year | 03 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000061501
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |